CBU
CRSP icon

CIBC Bancorp USA’s CRISPR Therapeutics CRSP Stock Holding History

CIBC Bancorp USA’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
6,922
+37
+0.5% +$1.95K ﹤0.01% 1418
2026
Q1 		$328K Buy
+6,885
New +$363K ﹤0.01% 1375
2025
Q3 		$572K Buy
+8,824
New +$507K ﹤0.01% 812

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CIBC Bancorp USA's CRSP Position: Q2 2026 in Review

CIBC Bancorp USA increased its CRISPR Therapeutics (CRSP) stake by 0.54% in Q2 2026, buying an estimated $1.95K and bringing the position to 6,922 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

CIBC Bancorp USA first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. The position peaked at $572K in Q3 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • CIBC Bancorp USA held 6,922 shares of CRISPR Therapeutics worth $378K as of Q2 2026.
  • CIBC Bancorp USA bought 37 CRISPR Therapeutics shares in Q2 2026, an estimated $1.95K.
  • CRISPR Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1418 holding.
  • CIBC Bancorp USA first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's CRISPR Therapeutics position peaked at $572K in Q3 2025.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.